The End of Abbvie's $200 Billion Monopoly Won't Sink the Stock
The drugmaker is offering steep discounts on its immune-disease therapy Humira to protect market share this year.
Source link
Published On: Fri, Feb 10th, 2023
Health | By Larry Pham
